Novo Nordisk shares tumbled after its heart drug Ziltivekimab failed a major late-stage trial, raising questions about the company's growth beyond weight-loss drugs and triggering a sharp market reaction
Investors betting that Novo Nordisk could expand its business beyond blockbuster weight-loss drugs faced a setback as the company's experimental heart drug, Ziltivekimab, failed to meet its primary goal in a pivotal late-stage trial. The Danish pharmaceutical giant announced on July 31 that the ZEUS trial, which tracked more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, did not show a reduction in major cardiovascular events compared to placebo. The news sent Novo Nordisk's shares tumbling, with Danish-listed shares down about 7.5% and U.S.-listed shares falling 8.6% in early trading, according to CNBC.
The ZEUS trial was designed to test whether Ziltivekimab, a once-monthly injection targeting the inflammatory protein IL-6, could lower the risk of heart attack, stroke, or cardiovascular death by reducing inflammation. While the drug did succeed in lowering inflammation markers, this biological effect did not translate into fewer adverse cardiovascular outcomes. The trial's hazard ratio of 0.99 indicated virtually no difference in risk between the drug and placebo groups. Additionally, patients receiving Ziltivekimab experienced a higher rate of serious infections, though overall mortality rates were similar across both groups.
Market Reaction and Financial Impact
The sharp decline in Novo Nordisk's stock price underscores how much investors were counting on Ziltivekimab to become a new growth engine alongside the company's established diabetes and obesity franchises, Wegovy and Ozempic. Analysts had widely expected at least some cardiovascular benefit from the drug, with hopes it could eventually generate billions in annual sales. The trial's failure now puts those expectations on hold and raises questions about the strength of Novo Nordisk's cardiovascular pipeline outside its core GLP-1 therapies.
Novo Nordisk stated it will take a non-cash impairment charge in the third quarter of 2026 as a result of the ZEUS trial outcome. An impairment charge is an accounting adjustment that reduces the book value of an asset, reflecting diminished prospects for future returns. Importantly, the company said this charge will not affect its adjusted operating profit outlook for 2026, suggesting that near-term earnings remain stable despite the setback.
Pipeline Pressure and Legal Risks
The disappointment comes at a challenging time for Novo Nordisk. The company's shares have already retreated from their 2024 highs as Eli Lilly has gained ground in the GLP-1 market with Mounjaro and Zepbound. The ZEUS trial miss follows a recent U.S. court decision requiring Novo Nordisk to face part of a shareholder lawsuit related to disclosures about its CagriSema weight-loss trial. That case centers on what Novo told investors about the design of the REDEFINE-1 trial before disappointing results were released in December 2024.
For investors, the concern is not just about a single failed trial but about a pattern of high expectations for pipeline drugs that have not always delivered. The ZEUS result adds to the pressure on Novo Nordisk to demonstrate that it can diversify its revenue base and maintain its competitive edge as rivals like Eli Lilly continue to expand their market share.
What's Next for Novo Nordisk's Heart Drug Program
Despite the ZEUS setback, Novo Nordisk is not abandoning its cardiovascular ambitions. Ziltivekimab remains in two other late-stage trials: HERMES, which is studying patients with heart failure, and ARTEMIS, which is focused on patients recovering from acute heart attacks. Results from these studies are expected in the first half of 2027. A positive outcome in either trial could revive hopes for the drug's future, but there is no guarantee that the results will differ from ZEUS.
Investors will be watching Novo Nordisk's next earnings report closely for details on the impairment charge and any updates to its pipeline strategy. Key areas to monitor include the financial impact of the ZEUS program write-down, prescription trends for the oral version of Wegovy, and developments in the ongoing CagriSema lawsuit. The company also plans to present full ZEUS trial data at a medical conference later in 2026, which may reveal whether any patient subgroups benefited from the drug.
While the failure of Ziltivekimab in the ZEUS trial does not threaten Novo Nordisk's current revenue streams, it removes a potential path for the company to widen its lead over competitors. The stock's recent decline may reflect that some of these risks were already priced in, but the outcome highlights the challenges of relying on pipeline breakthroughs to drive future growth. As with other high-profile disappointments-such as when Netflix shares dropped after a cautious sales outlook, as discussed in this analysis-investors must weigh whether the current valuation adequately reflects both the setbacks and the remaining opportunities.
According to Novo Nordisk's 2025 annual report, the company generated more than $33 billion in global revenue, with over 80% coming from diabetes and obesity treatments. The cardiovascular pipeline, including Ziltivekimab, was seen as a key area for future diversification. The impairment charge related to the ZEUS trial is expected to be disclosed in the third quarter 2026 financials, but the company has reaffirmed its full-year profit guidance.
Drug development in the cardiovascular space is notoriously challenging, with many promising candidates failing to deliver meaningful clinical benefits in large trials. For pharmaceutical companies like Novo Nordisk, the stakes are high: a successful new therapy can open multi-billion-dollar markets, but setbacks can quickly erase years of investment and shift investor sentiment. The risk-reward profile for pipeline drugs is a central consideration for both company strategy and shareholder decisions, especially as competition intensifies in established therapeutic areas.
